drugset / Trial / NCT05160506

Corticosteroids to Treat Pancreatitis

NCT05160506

Phase 2 Recruiting 86 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Timeline

Start
2022-03-06
Primary completion
2027-01
Completion
2027-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocortisone Other / unclassified 100 mg Intravenous

Indications